• Wondering if TG Therapeutics at around US$34.30 is pricing in too much hope or not enough future potential? This article breaks down what that current tag may actually reflect.
• The stock has been volatile, with a 1% decline over the last 7 days, an 8.9% gain over 30 days, a 17.1% gain year to date, but a 10.5% decline over the past year and a 16.5% decline over 5 years, all against a 60.4% gain over 3 years.
• Recent news coverage around TG Therapeutics has focused on its position within the biotech sector and how its pipeline and approvals story influence investor sentiment. That backdrop helps explain why the share price has swung between periods of optimism and caution.
• TG Therapeutics currently scores a 5 out of 6 on our valuation checks, and the sections that follow will compare different valuation methods before looking at an even better way to make sense of these numbers.

Approach 1: TG Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model looks at the cash TG Therapeutics is expected to generate in the future and then discounts those projected amounts back to what they could be worth in today’s dollars.

For TG Therapeutics, the latest twelve month free cash flow is a loss of $24.9 million. Analysts provide explicit free cash flow estimates for several years, and these are then extended by Simply Wall St to create a longer 10 year path. On that basis, projected free cash flow reaches $651.3 million in 2030, with annual figures between 2026 and 2035 ranging from about $239.7 million to $900.2 million before discounting.

Using this 2 Stage Free Cash Flow to Equity model, the estimated intrinsic value comes out at about $110.95 per share. Against a current share price of roughly $34.30, this DCF output suggests TG Therapeutics trades at a 69.1% discount to that estimate, which indicates that, on this specific cash flow based approach, the shares appear undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests TG Therapeutics is undervalued by 69.1%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Approach 2: TG Therapeutics Price vs Earnings

For a profitable company, the P/E ratio is a useful quick check because it tells you how much you are paying for each dollar of current earnings. Investors usually accept a higher P/E when they expect stronger growth or see lower risk, and look for a lower P/E when growth expectations are modest or risks are higher.

TG Therapeutics currently trades on a P/E of 11.33x. That sits below both the Biotechs industry average P/E of 17.20x and a peer group average of 38.12x, which indicates the market is valuing its earnings more cautiously than many comparable names.

Simply Wall St’s Fair Ratio for TG Therapeutics is 17.37x. This is a proprietary estimate of what a “normal” P/E might look like after accounting for factors such as the company’s earnings growth profile, industry, profit margins, market cap and specific risks. Because it pulls these elements together, the Fair Ratio can be more informative than a simple comparison with industry or peer averages, which may not reflect the company’s own characteristics.

Comparing the Fair Ratio of 17.37x with the current P/E of 11.33x shows the shares trade below that tailored reference point, which indicates the stock appears undervalued on this measure.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your TG Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to set out your story for TG Therapeutics, link that story to specific forecasts for revenue, earnings and margins, and then see the fair value that falls out of those assumptions.

A Narrative on Simply Wall St’s Community page lets you describe why you think the business might evolve in a certain way, tie that view to concrete numbers, and then compare the resulting fair value with the current share price to help you judge whether the stock looks expensive or inexpensive on your terms.

Because Narratives sit on the same platform used by millions of investors, they offer an accessible tool where the fair value output updates when new earnings, news or guidance are entered into the model. This means your story and the valuation attached to it stay current without extra work from you.

For TG Therapeutics, one investor might anchor their Narrative closer to a cautious fair value of about US$17.32, while another might lean toward a higher case around US$60. Both can clearly see how their different views on future revenue, margins, P/E and risk translate into very different fair values and potential decisions about when the current price looks attractive or stretched.

For TG Therapeutics however we will make it really easy for you with previews of two leading TG Therapeutics Narratives:

Fair value in this bullish Narrative: US$44.43 per share.

At a last close of US$34.30, the price sits about 22.8% below that fair value estimate.

Revenue growth assumption: 33.19% a year.

• Views the upcoming subcutaneous BRIUMVI launch and expanding access as key drivers that could widen the treated MS population and support higher long term revenue.
• Assumes solid revenue growth with margins settling at 31.7%, and earnings reaching about US$461.7m by 2029 on a future P/E of 18.1x.
• Highlights risks from heavy reliance on BRIUMVI, pricing and reimbursement pressure, and intensifying MS competition, but still sees US$44.43 as a central fair value anchor.

Fair value in this bearish Narrative: US$17.32 per share.

At a last close of US$34.30, the price sits about 98.4% above that fair value estimate.

Revenue growth assumption: 32.28% a year.

• Focuses on exposure to BRIUMVI pricing pressure, tighter reimbursement, rising costs and patent expiry risk, which could weigh on margins and future earnings.
• Builds in earnings of about US$319.8m by 2029, with margins compressing to 22.4% and a lower future P/E of 10.2x, pointing to a US$17.32 fair value that sits well below consensus.
• Recognises that strong BRIUMVI uptake, new indications and subcutaneous development could challenge this view, so encourages you to stress test the assumptions rather than take the bearish case at face value.

Taken together, these two Narratives frame a wide but clearly quantified range around TG Therapeutics, and your own view on BRIUMVI concentration risk, future pricing, and long term earnings power will determine where you sit between them. See what the community is saying about TG Therapeutics

Do you think there's more to the story for TG Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.